flecainide (tambocor) Report issue

Small molecule Approved FDA
AACT ChEMBL DrugBank Drug Central Drugs@FDA KEGG MeSH PubChem repoDB

Active Ingredient History

NOW
  • Now
Flecainide is a potent anti-arrhythmia agent, effective in a wide range of ventricular and atrial arrhythmias and tachycardias. Flecainide has local anesthetic activity and belongs to the membrane stabilizing (Class 1) group of antiarrhythmic agents; it has electrophysiologic effects characteristic of the IC class of antiarrhythmics. Flecainide acts on sodium channels on the neuronal cell membrane, limiting the spread of seizure activity and reducing seizure propagation. The antiarrhythmic actions are mediated through effects on sodium channels in Purkinje fibers. Flecainide is a sodium channel blocker, binding to voltage gated sodium channels. It stabilizes the neuronal membrane by inhibiting the ionic fluxes required for the initiation and conduction of impulses. Ventricular excitability is depressed and the stimulation threshold of the ventricle is increased during diastole. Flecainide is sold under the trade name Tambocor (manufactured by 3M pharmaceuticals). Flecainide went off-patent on February 10, 2004. In addition to being marketed as Tambocor, it is also available in generic version and under the trade names Almarytm, Apocard, Ecrinal, and Flécaine.   NCATS

Chemistry

  • SMILES: FC(F)(F)COc1ccc(OCC(F)(F)F)c(c1)C(=O)NCC2CCCCN2
  • InChIKey: DJBNUMBKLMJRSA-UHFFFAOYSA-N
  • Mol. Mass: 414.35
  • ALogP: 3.44
  • ChEMBL Molecules:
    flecainide  
    flecainide acetate  
More Chemistry

Pharmacology

  • Mechanism of Action:
  • Multi-specific: Missing data
  • Black Box: Yes
  • Availability: Prescription Only
  • Delivery Methods: Oral
  • Pro Drug: No

Drug Pricing (per unit)

United States

$0.1281 - $1.2802

Australia

$0.2956 - $0.3665
More Pricing Detail

Note: This drug pricing data is preliminary, incomplete, and may contain errors.

Alternative names

ccris 313 | flecaine | flecainida | flecainide | (+-)-flecainide | flecainide acetate | flecainidum | n-(2-piperidinylmethyl)-2,5-bis(2,2,2-trifluoroethoxy)benzamide | tambocor

Organizations (80)

Research & Development (68)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (12)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (23)

Approved Indications (3)


 

Arrhythmias, Cardiac (approved 2001)

Atrial Fibrillation (approved 2001)

Wolff-Parkinson-White Syndrome

Experimental Indications - Clinical Trial Phases 1-4 (22)


 

Ablation Techniques (Phase 2)

Arrhythmias, Cardiac (Phase 3)

Arrhythmogenic Right Ventricular Dysplasia (Phase 2)

Atrial Fibrillation (Phase 4)

Brugada Syndrome (Phase 4)

Cardiomyopathies (Phase 4)

Cardiovascular Diseases (Phase 3)

Carvedilol (Phase 4)

Coronary Disease (Phase 3)

Death, Sudden, Cardiac (Phase 3)

Fetal Development (Phase 3)

Heart Arrest (Phase 3)

Heart Diseases (Phase 4)

Lung Neoplasms (Phase 2)

Myocardial Infarction (Phase 3)

Myocardial Ischemia (Phase 3)

Pain (Phase 2)

Recurrence (Phase 2/Phase 3)

Tachycardia (Phase 3)

Tachycardia, Ventricular (Phase 4)

Ventricular Outflow Obstruction (Phase 4)

Ventricular Premature Complexes (Phase 4)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 40
  • # of Trial Organizations: 68

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue